Search Within

Andrew D Zelenetz

  1. "Executive Committee, Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (34)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (106)
  2. Department of Medicine (106)
  3. Executive Committee, Center for Hematologic Malignancies (106)
  4. Hematologic Malignancies, Division of (106)
  5. Lymphoma (106)
  6. Survivorship Research (72)

More Groups

People
  1. Anas Younes (88)
  2. Maria Palomba (72)
  3. Matthew Matasar (69)
  4. Paul Hamlin (64)
  5. Anita Kumar (63)
  6. Ariela Noy (63)

More People

Years
  1. 2024 (3)
  2. 2023 (3)
  3. 2022 (10)
  4. 2021 (9)
  5. 2020 (11)
  6. 2019 (16)

More Years

Publications
  1. Blood (48)
  2. Hematological Oncology (11)
  3. Journal of Clinical Oncology (6)
  4. Blood Cancer Journal (5)
  5. Leukemia and Lymphoma (5)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (51)
  2. Wiley Blackwell (11)
  3. Nature Publishing Group (9)
  4. American Society of Clinical Oncology (6)
  5. Taylor & Francis Group (5)
  6. American Association for Cancer Research (4)

More Publishers

Results (106)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
    Journal Article

    Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status
    Meeting Abstract

    Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save